Method for cellular RNA expression
The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.
1. A method for providing cells having stem cell characteristics comprising the steps of (i) providing a cell population comprising somatic cells, (ii) preventing engagement of IFN receptor of the somatic cells by extracellular IFN by providing vaccinia virus B18R to the somatic cells in the form of first RNA encoding vaccinia virus B18R, (iii) inhibiting intracellular IFN signaling in the somatic cells by providing vaccinia virus E3 to the somatic cells in the form of second RNA encoding vaccinia virus E3 and by providing vaccinia virus K3 to the somatic cells in the form of third RNA encoding vaccinia virus K3, (iv) providing to the somatic cells further RNA capable of expressing one or more factors allowing the reprogramming of the somatic cells into cells having stem cell characteristics, and (v) allowing the development of cells having stem cell characteristics, wherein the ribonucleotides of the first, second, and third RNAs are simultaneously introduced into the somatic cells and wherein the further RNA comprises naturally occurring nucleotides.
2. The method of claim 1 , wherein the one or more factors comprise OCT4 and SOX2.
3. The method of claim 2 , wherein the one or more factors further comprise KLF4 and/or c-MYC.
4. The method of claim 3 , wherein the one or more factors further comprise NANOG and/or LIN28.
5. The method of claim 1 , wherein the one or more factors comprise OCT4, SOX2, KLF4 and c-MYC.
6. The method of claim 4 , wherein the one or more factors further comprise LIN28 and optionally NANOG.
7. The method of claim 1 , wherein the one or more factors comprise OCT4, SOX2, NANOG and LIN28.
8. The method of claim 1 , further comprising the step of culturing the somatic cells in the presence of at least one histone deacetylase inhibitor.
9. The method of claim 8 , wherein the at least one histone deacetylase inhibitor comprises valproic acid.
10. The method of claim 1 , wherein step (v) comprises culturing the somatic cells under embryonic stem cell culture conditions.
11. The method of claim 1 , wherein the stem cell characteristics comprise an embryonic stem cell morphology.
12. The method of claim 1 , wherein the cells having stem cell characteristics have normal karyotypes, express telomerase activity, express cell surface markers that are characteristic for embryonic stem cells and/or express genes that are characteristic for embryonic stem cells.
13. The method of claim 1 , wherein the cells having stem cell characteristics exhibit a pluripotent state.
14. The method of claim 1 , wherein the cells having stem cell characteristics have the developmental potential to differentiate into advanced derivatives of all three primary germ layers.
15. The method of claim 1 , wherein the somatic cells are fibroblasts.
16. The method of claim 15 , wherein the fibroblasts are lung fibroblasts, foreskin fibroblasts or dermal fibroblasts.
17. The method of claim 1 , wherein the somatic cells are human cells.
18. The method of claim 1 , wherein the first, second, third and/or further RNA comprises a 5′CAP.
19. The method of claim 1 , wherein the RNA capable of expressing one or more factors is repetitively introduced into the cells.